Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 7.19% | 19.10% | 1.74% | 1.74% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 28.96% | 5.95% | 6.34% | 6.34% | |
| Operating Income | -28.96% | 3.96% | 321.88% | 321.88% | |
| Income Before Tax | -12.33% | -1.15% | 320.59% | 320.59% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -11.30% | -0.02% | 317.07% | 317.07% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -11.30% | -0.02% | 317.07% | 317.07% | |
| EBIT | -28.96% | 3.96% | 321.88% | 321.88% | |
| EBITDA | -31.47% | 3.23% | 335.34% | 335.34% | |
| EPS Basic | 82.43% | 90.66% | 120.93% | 120.93% | |
| Normalized Basic EPS | -18.03% | 13.88% | 319.98% | 319.98% | |
| EPS Diluted | 79.89% | 90.66% | 114.67% | 114.67% | |
| Normalized Diluted EPS | -18.03% | 13.88% | 258.97% | 258.97% | |
| Average Basic Shares Outstanding | 5.07% | 5.03% | 4.49% | 4.49% | |
| Average Diluted Shares Outstanding | 5.07% | 5.03% | 44.58% | 44.58% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
